LEGN (Legend Biotech) Market Value to Book Value Ratio

Official company branding of Legend Biotech (LEGN)

Legend Biotech (LEGN) production capacities are operating at peak efficiency, while the expansion of sterile zones allows the company to meet growing demand. The linear price action on the chart confirms the success of Carvykti in the myeloma therapy segment, where the business relies on partnerships with clinics and patients, and the metric stands at 3.19. Long-term profit is based on the ownership of patents for unique treatment methods that have become the indispensable standard.

Legend Biotech Corp. (LEGN): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for Legend Biotech Corp (LEGN)

- price and consensus price forecast:
Price Chart Legend Biotech|LEGN - Broker Consensus Forecast
- market capitalization data:
Market Value Legend Biotech Inc.|LEGN - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Legend Biotech|LEGN - Accounting Capitalization|Market Capitalization to Book Value Ratio legendbiotech.com|LEGN - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Legend Biotech|LEGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Legend Biotech Inc.|LEGN - Company Debts|Debt to Book Capitalization Ratio Legend Biotech Inc.
Fundamental valuation:Legend Biotech
Brand item of Legend Biotech Inc.

This metric is calculated as the ratio of the total market capitalization to net equity, measuring the premium of market expectations over the book value of assets. The current value of 3.19 reflects a high valuation of intellectual capital and CAR-T patents, which, combined with strict FDA oversight, makes the dynamics of the market-to-book ratio a key indicator of the investment potential resilience of Legend Biotech (LEGN).

Competitor analysis

Market Value to Book Value Ratio Sana Biotechnology|AUTL (autolus.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio ALLO (Allogene)|Market-to-Book Ratio RNAC|Market Value to Book Value Ratio Cellectis S.A. CLLS|Capitalization to Book Value Ratio Caribou Biosciences, Inc (CRBU)|Instil Bio, Inc. - Market Capitalization to Book Value Ratio|Genenta Science SpA - Market Cap to Net Assets Ratio|IPSC (Century Therapeutics Inc) - Market Value to Book Value Ratio|JSPR: Market-to-Book Ratio|sentibio.com (SNTI) - Market Value to Book Value Ratio|ADAP (Adaptimmune Therapeutics) - Market Value to Book Value Ratio|Market Value to Book Value Ratio CERO (CERo Therapeutics Holdings, Inc.)|Market-to-Book Ratio Alaunos|ACHL: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio CARGO Therapeutics Inc. CRGX|PSTX: Market Cap to Net Assets Ratio|TSVT - Market-to-Book Ratio|Market Cap to Net Assets Ratio Gracell Biotechnologies (GRCL)